Oculis Holding AG
OCSNext catalyst
licaminlimab
Dry Eye Disease
Get an email about OCS's next catalysts
Track Oculis Holding (OCS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 3 readout).See the timeline
3 upcoming, 0 past
OCS Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.49 | FQ end Sep/2026 | Call: tbd
licaminlimab Phase 3 Est. Readout
Primary completion for licaminlimab trial (NCT07548632) in Dry Eye Disease (DED)
Sourcelicaminlimab Phase 3 Est. Readout (PREDICT-1)
Estimated primary completion for licaminlimab trial (NCT07548632) in Dry Eye Disease (DED). Topline data typically follows completion by weeks to months.
SourceHow OCS's past catalysts played out
Market Overview
Stock performance and key metrics
Dexamethasone ophthalmic suspension (OCS-01)
Diabetic Macular Edema
licaminlimab
Dry Eye Disease
Privosegtor
Optic Neuritis
OCS-01
Inflammation Eye Pain
Dexamethasone nanoparticles eye drops
Diabetic Macular Edema
OCS-05 +SoC (corticosteroid) IV administration
Optic Neuritis
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension mg/mL
Inflammation Corneal
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Dexamethasone ophthalmic suspension (OCS-01) | Phase 3 | Diabetic Macular Edema | - | - |
licaminlimab | Phase 3 | Dry Eye Disease | - | - |
Privosegtor | Phase 3 | Optic Neuritis | - | - |
OCS-01 | Phase 3 | Inflammation Eye Pain | - | - |
Dexamethasone nanoparticles eye drops | Phase 2 | Diabetic Macular Edema | - | - |
OCS-05 +SoC (corticosteroid) IV administration | Phase 2 | Optic Neuritis | - | - |
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension mg/mL | Phase 2 | Inflammation Corneal | - | - |
Frequently asked questions
What is in Oculis Holding AG's drug pipeline?→
CatalystAlert tracks 7 drug candidates in Oculis Holding AG's (OCS) pipeline across Phase 3, Phase 2. Its lead program is licaminlimab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Oculis Holding AG's next FDA catalyst?→
Oculis Holding AG's (OCS) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track OCS biotech catalysts?→
Add OCS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Oculis Holding AG's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.